Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
L19TNF (also known as Fibromun) is an innovative immunotherapy, discovered and developed by Philogen
The new peer-reviewed scientific publicationpresentsrecentpreclinical and translational results obtained in glioblastoma, the most common and most aggressive primary brain tumor in adultsand represents the follow up story of the Science Translational Medicine paper reported in 2020 (see here)
Durable major responses are being observed in a proportion of patients enrolled in the Phase I part of the ongoing clinical trial (NCT04573192)
Siena (Italy), May24, 2023 - Philogen S.p.A. (BIT:PHIL), a clinical-stage biotech company focused on the development of innovative medicines based on tumor-targeting antibody and small molecule ligands, announces the publication of the latest results of Fibromun (L19TNF, Onfekafusp alfa) in combination with lomustine (an alkylating agent) for the treatment of glioblastoma in Science Translational Medicine describing how the combination treatment cured orthotopic glioma-bearing mice and mediated durable objective responses and major tumor shrinkage in patients with recurrent glioblastoma. The paper can be accessed at the following link.
The study demonstrated that the combination Fibromun and lomustine was highly synergistic and relied on an intact immune system. A thorough investigation of the treatment's mechanism of action showed that it could transform tumors from being "invisible" to the immune system ("cold") into being easily recognized and attacked ("hot"). This transformation was proven by several indicators: the activation of the tumor endothelium, enhanced tumor DNA damage signaling pathways, treatment-associated tumor necrosis, increased immunogenicity of cancer cells and elevation of immune cell infiltration within the neoplastic mass.
Prof. Michael Wellerand Dr. Tobias Weissof University Hospital Zürich, commented: “We are excited to release thisfollow-up work based on the Science Translational Medicine paper published together with Philogen back in 2020. The preclinical anti-tumor activity of the combination of Fibromunwith lomustine chemotherapy is very promising and the emerging clinical results of the ongoing Phase I/IItrialNCT04573192provide hope for better therapeutic opportunities for patients affected by this serious disease. We now look forward to exploring this promising approach in the Phase II randomized part which is currently starting.”
Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: “These latest findingsshow the promising potential of Fibromunfor the treatment of glioblastoma, one of the biggest unmet medical needs.While the Phase II randomized part of theGLIOSTAR clinical trialis about to start, the preliminary evidence collected in the Phase I part demonstrates encouraging, durable objective responses in an indication where responses are very rare. We are committed to advancing our research and development efforts, with the ultimate goal of delivering this innovative treatment to patients in need."
* * *
About L19TNF (also known as Fibromun)
L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and tumor necrosis factor (TNF), a strong pro-inflammatory cytokine. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs. The product is currently investigated in multiple clinical trials for the treatment of soft tissue sarcoma and glioblastoma, both in Europe and in the United States.
Glioblastoma is the most common and most aggressive primary brain tumor. It affects approximately 5 out of 100’000 people every year (Source: Orphanet). Newly diagnosed patients are typically treated with surgery, radiation and temozolomide (chemotherapy), which result in a median Overall Survival (mOS) in the range of 15 months. Virtually all patients progress and may subsequently receive another systemic or local second-line therapy. The mOS of patients at first progression ranges between 4.7 and 9.8 months in previous clinical trials.
About clinical trialNCT04573192
The Phase I/II clinical trial NCT04573192, which investigates the combination of L19TNF and lomustine for the treatment of patients suffering from glioblastoma at first progression after standard of care radiotherapy and chemotherapy. The Phase I part of the trial with escalating dose levels of L19TNF and lomustine is followed by a randomized Phase II part to investigate the efficacy of the combination treatment compared to standard of care lomustine as monotherapy with overall survival as primary endpoint. The first cohort of the phase I part of the study, comprising 6 patients, is presented in this publication.
About the Philogen Group
Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-EncodedChemical Library technologies.
The Group's main therapeutic strategy for the treatment of these diseases is represented by the so-called tumor targeting. This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so called vascular targeting, is used for most of the projects pursued by the Group.
The Group's objective is to generate, develop and market innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights.
Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases.
* * *
FOR MORE INFORMATION:
Philogen - Investor Relations
IR@philogen.com - Emanuele Puca | Investor Relations
Consilium Strategic Communications contacts
Mary-Jane Elliott, Davide Salvi
* * *
The forward-looking statements contained in this press release may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; anticipated enrollment in and progression of Philogen’s clinical trials; the availability of data from clinical trials and preclinical studies; anticipated regulatory filings; the therapeutic potential of Philogen’s product candidates; Philogen’s ability to achieve planned milestones. Philogen may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Philogen’s and its partners’ abilities to meet other anticipated deadlines and milestones, also due to the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Philogen’s product candidates by Philogen or its partners; the risk that Philogen may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Philogen’s product candidates; risks related to Philogen’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; other factors which could cause our actual result to differ from those contained in the forward-looking statements, as also described in greater detail in the Risk Factors section in the prospectus drafted by Philogen and approved by Consob on February 17, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Philogen expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. The information and contents of this press release do not: (i) constitute an order or an offer to purchase or to sell financial products or financial services; (ii) relate to special investment goals or to the financial situation or particular requirements of specific users. All information presented, reports published, and opinions expressed are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the press release is not to be understood as an invitation or recommendation to buy or sell securities of Philogen, or as an advertisement for securities of Philogen. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives. The mere use of the website does not give rise to any contractual relationship of any kind between the user and Philogen. Philogen expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. Philogen provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision. The material contained on the website does not relieve the user from having to make his own decisions. This press release may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of Philogen. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. Philogen accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties and gives no assurances of any kind in this regard. Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
WithSecure Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 106.6.2023 08:30:00 CEST | Press release
WithSecure Corporation, Stock Exchange Release, 6 June 2023, at 9.30 EEST WithSecure Corporation: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 WithSecure Corporation has received an announcement from Nordea Funds Ltd. on 2 June 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total number of votes held by Nordea Funds Ltd. decreased to below ten (10) per cent of the total number of votes of WithSecure Corporation on 1 June 2023. Total position of Nordea Funds Ltd. subject to the notification: % of shares and voting rights % of shares and voting rights through financial instruments % of totalTotal number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached Shares: 9.59% Votes: 9.90% Shares: 9.59% Votes: 9.90% 176,098,739.00 Position of previous notification (if applicable) Shares: 9.81% Votes: 10.12% Shares: 9.81% Votes: 10.12% Noti
Equinor ASA: Share buy-back6.6.2023 08:00:00 CEST | Press release
Please see below information about transactions made under the share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR). Date on which the second tranche of the share buy-back programme for 2023 was announced: 4 May 2023. The duration of the second tranche of the buy-back programme for 2023: 11 May to no later than 25 July 2023. Size of the buy-back programme: Up to 94,000,000 shares, with a maximum total consideration for the second tranche: USD 550,000,000. From 29 May to 2 June, Equinor ASA has purchased a total of 2,117,395 own shares at the Oslo Stock Exchange at an average price of NOK 288.2593 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)29 May30 May510,000292.4021149,125,071.0031 May560,000284.7080159,436,480.001 June550,000284.5167156,484,185.002 June497,395292.1483145,313,103.68Previously disclosed buy-backs under the second tranche of the 2023 programme 4,0
Progress on share buyback programme6.6.2023 08:00:00 CEST | Press release
Progress on share buyback programme ING announced today that, in line with the launch of our €1.5 billion share buyback programme announced on 11 May 2023, we repurchased 1,711,037 shares during the week of 29 May 2023 up to and including 2 June 2023. The shares were repurchased at an average price of €11.81 for a total amount of €20,199,121.24. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at www.ing.com/investorrelations. The total number of shares repurchased under this programme to date is 5,466,433 ordinary shares at an average price of €11.91 for a total consideration of €65,084,362.50. To date approximately 4.34% of the maximum total value of the share buyback programme has been completed. Note for editors For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom or via the @ING_news Twitter feed. Photos of ING operations, buildings and it
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference6.6.2023 08:00:00 CEST | Press release
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, 11:20 AM PDT on June 13, 2023 (2:20 PM EDT / 8:20 PM CEST). A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function
Sampo plc’s share buybacks 05/06/20236.6.2023 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 06/06/2023 at 08:30 am Sampo plc’s share buybacks 05/06/2023 On 05/06/2023 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)7,94943.63AQEU31,84643.50CEUX13,65043.61TQEX66,55543.52XHELTOTAL120,00043.53 *rounded to two decimals On 29 March 2023, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 3 April 2023, is based on the authorisation granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 4,530,623 Sampo A shares representing 0.89 per cent of the total number of shares in Sampo plc. Details o